AstraZeneca has proposed designs for its new Global R&D center and corporate headquarters in Cambridge, UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the global center, an R&D enabling building, and an energy center.
The new site will bring together AstraZeneca’s small molecule and biologics research and development activity, opening up more opportunities for biologics and small molecule combinations. The CBC will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune currently employs around 500 people at Granta Park, to the southeast of the city.
In advance of the new site to be finished in late 2016, around 70 AstraZeneca staff have already relocated to interim facilities in Cambridge, at the Melbourn Science Park, Cambridge Science Park, and Granta Park. By the end of 2014 approximately 300–400 AstraZeneca staff will have relocated to the city.
Designs for AstraZeneca’s new site are being made available as part of a public consultation for the local community, ahead of submission of a detailed planning application in autumn 2014. AstraZeneca expects to begin building the new site in early 2015.